hims semaglutide shortage Hims - HimsGLP pill Shares of Hims & Hers Health closed down around 26 Navigating the Hims Semaglutide Shortage: What You Need to Know

HimsGLP pill The landscape of weight management and type 2 diabetes treatment has been significantly impacted by the availability of semaglutide. For a period, the hims semaglutide shortage created considerable uncertainty and concern for many individuals relying on these medications. This article aims to provide a comprehensive overview of the situation, drawing on the latest information regarding the shortage, Hims & Hers's role, and regulatory actions taken by the FDAHims & Hers Looks to Drive Growth Via International ....

Understanding the Semaglutide Shortage and Hims's Involvement

The semaglutide shortage emerged as a major challenge, affecting both branded and compounded versions of the drug.2025年8月19日—The FDA ended thesemaglutide shortage on Feb 21, 2025. Learn key deadlines for compounded semaglutide, GLP-1 alternatives and more. Hims, an online health and wellness platform, became a prominent figure in this narrative due to its offerings of compounded GLP-1 medications, including semaglutide. When branded GLP-1 medications are challenging to access across the country, platforms like Hims stepped in with compounded alternatives. This strategy, while initially popular, also drew regulatory scrutiny.

The shortages of semaglutide and other GLP-1 drugs like tirzepatide led to a surge in demand for compounded versions.Americans Continue to Struggle to Access Branded GLP ... Hims was at the forefront of bringing compounded versions of GLP-1 weight-loss drugs into the mainstream. However, this period was marked by significant disruptions.Hims & Hers Snaps EPS Losing Streak but Shares Still in ... Shares of Hims & Hers Health closed down around 26% following FDA announcements regarding the semaglutide shortage2025年4月16日—Online telehealth platformHims & Hers has confirmed it will keep offering compounded semaglutideto eligible patients despite the upcoming FDA restrictions.. Similarly, shares of Hims & Hers Health tumbled more than 23% on multiple occasions as news of the resolution of the shortage and subsequent regulatory actions emerged.

FDA's Stance and Regulatory Actions

The U.S. Food and Drug Administration (FDA) has played a crucial role in addressing the semaglutide shortage and the subsequent market dynamics. The FDA officially declared the semaglutide shortage over on Feb 21, 2025. This announcement signaled a turning point for both patients and companies like Hims.

The FDA also issued warnings regarding unapproved drugs containing semaglutide, tirzepatide, or retatrutide that were falsely labeled "for research." Furthermore, the FDA moved to restrict GLP-1 ingredients used in compounded drugs. This regulatory action has had a direct impact on companies like Hims, which had been offering compounded versions. Hims has stopped offering the compounded pill in response to FDA warnings and potential restrictions. This also led to Novo Nordisk filing a patent infringement suit against Hims & Hers after the FDA resolved the semaglutide shortage and initiated moves to restrict copycat compounded versions. Novo Nordisk alleged that Hims & Hers continued to unlawfully mass compound injectable semaglutide made with inauthentic API, even after Hims claimed to have ceased offering the compounded pill.8天前—The FDA officially removed tirzepatide from the shortage list in December 2024 andremoved semaglutide in February 2025. Yet compounding ...

The End of the Shortage and What Comes Next

The resolution of the semaglutide shortage on Feb 21, 2025, marks a significant shift in the market. Novo Nordisk's semaglutide shortage officially concludes, meaning Wegovy and Ozempic, the branded semaglutide drugs, are no longer in short supply. This situation has led to a reassessment of business strategies for companies like Hims.

Despite the FDA's actions and Novo Nordisk's legal challenges, Hims & Hers has confirmed it will keep offering compounded semaglutide to eligible patients, indicating a nuanced approach to navigating the evolving regulatory environment. However, the company is officially phasing out its copycat weight-loss drugs. Compounders like Hims had a grace period of 60-90 days after the FDA removed semaglutide injection products from the shortage list to stop making copies.1天前—Novo alleged thatHims& Hers has continued to “mass compound injectable versions [of Novo's Wegovy (semaglutide)] made with inauthentic API” ...

The semaglutide shortage could be lifted any day, as predicted by data analysis, and its resolution has significantly altered the availability of these critical medications. The FDA removed semaglutide in February 2025, ending a period of considerable strain on supply.

Key Takeaways and Future Outlook

The hims semaglutide shortage saga highlights the complexities of drug supply chains, the role of compounding pharmacies, and the regulatory oversight required to ensure patient safety and access to legitimate treatments. While the semaglutide shortage has been officially declared over, the long-term implications for companies that relied heavily on compounded versions, such as Hims, are still unfolding.

Individuals seeking semaglutide should consult with healthcare professionals to understand their treatment options, including the availability of branded medications and the risks and benefits associated with any compounded alternatives2026年2月4日—FDA has warned companies that have illegally sold unapproved drugs containingsemaglutide, tirzepatide or retatrutide that are falsely labeled “for research .... The semaglutide shortage resolved in February 2025, offering a more stable supply of the medication. However, the regulatory environment surrounding compounded drugs remains dynamic. The semaglutide shortage decision has created a new reality for Hims, and their ability to adapt will be key to their future.